Načítá se...
Ranolazine Attenuates Behavioral Signs of Neuropathic Pain
Ranolazine modulates the cardiac voltage-gated sodium channel (Na(v) 1.5) and is FDA-approved for the treatment of ischemic heart disease. Ranolazine also targets neuronal (Na(v) 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2009
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2975014/ https://ncbi.nlm.nih.gov/pubmed/19773645 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FBP.0b013e3283323c90 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|